Stock comparison
Haemonetics
Veracyte
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
VCYT
Veracyte
Market cap
$3.59B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | VCYT | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 50D | HAE |
| Benjamin Graham | 85A | 61D | HAE |
| Philip Fisher | 60C | 65C | VCYT |
| Peter Lynch | 54C | 72B | VCYT |
| Joel Greenblatt | 31F | 50D | VCYT |
| Charlie Munger | 54D | 51D | HAE |
| Terry Smith | 55D | 56D | VCYT |
Side-by-side metrics
| Metric | HAE | VCYT |
|---|---|---|
| Market cap | $2.98B | $3.59B |
| P/E (TTM) | 24.8x | 34.8x |
| EV/EBIT | 14.1x | 38.4x |
| ROIC (TTM) | 8.37% | 4.73% |
| Gross margin | 55.74% | 71.31% |
| Net margin | 7.29% | 16.25% |
| Revenue CAGR 5y | 7.65% | 23.89% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 38.4x+63%
- ROIC (TTM)8.37%vs 4.73%+44%
- P/E (TTM)24.8xvs 34.8x+29%
VCYT leads on
- Debt / Equity0.0xvs 1.5x+98%
- Revenue CAGR 5y23.89%vs 7.65%+68%
- Net margin16.25%vs 7.29%+55%
- Gross margin71.31%vs 55.74%+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.